Monoclonal Gammopathy of Uncertain Significance disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MGUS MCID: MNC006 MIFTS: 43	Monoclonal Gammopathy of Uncertain Significance (MGUS) Categories: Blood diseases, Cancer diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Monoclonal Gammopathy of Uncertain Significance

MalaCards integrated aliases for Monoclonal Gammopathy of Uncertain Significance:

Name: Monoclonal Gammopathy of Uncertain Significance ¹¹ ¹⁴

Monoclonal Gammopathy of Undetermined Significance ¹¹ ¹⁹ ⁷⁵ ⁷¹ ³¹ ³³

Mgus ¹¹ ¹⁹

Mgus - [monoclonal Gammopathy of Undetermined Significance] ³³

Monoclonal Gammoglobulinopathy ³³

Monoclonal Gammopathy Nos ³³

Iga Gammopathy ³³

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Neoplasms of uncertain or unknown behaviour

Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue

Monoclonal gammopathy of undetermined significance (MGUS)

ICD11: ³³

Neoplasms

Neoplasms of haematopoietic or lymphoid tissues

Mature B-cell neoplasms

Plasma cell neoplasms

Monoclonal gammopathy of undetermined significance

External Ids:

Disease Ontology ¹¹ DOID:7442

ICD10 ³¹ D47.2

ICD11 ³³ 45411563

UMLS ⁷¹ C0026470

Sources

Summaries for Monoclonal Gammopathy of Uncertain Significance

GARD: ¹⁹ Monoclonal gammopathy of undetermined significance (MGUS) is a condition in which an abnormal protein called monoclonal protein is detected in the blood. MGUS typically does not cause any problems, although some affected people may experience numbness, tingling or weakness. In some cases, MGUS may progress over time to certain forms of blood cancer (such as multiple myeloma, macroglobulinemia, or B-cell lymphoma). MGUS is thought to be a multifactorial condition that is likely associated with the effects of multiple genes in combination with lifestyle and environmental factors. People with MGUS are usually monitored closely to ensure that the levels of monoclonal protein do not rise and other problems do not develop.

MalaCards based summary: Monoclonal Gammopathy of Uncertain Significance, also known as monoclonal gammopathy of undetermined significance, is related to agammaglobulinemia and thrombocytopenia due to platelet alloimmunization. An important gene associated with Monoclonal Gammopathy of Uncertain Significance is MYOM2 (Myomesin 2), and among its related pathways/superpathways are NF-kappaB Signaling and Mesenchymal Stem Cells and Lineage-specific Markers. The drugs Celecoxib and Sodium fluoride have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and liver, and related phenotypes are immune system and hematopoietic system

Disease Ontology: ¹¹ A blood protein disease that is characterized by the presence of an abnormal protein called monoclonal protein in the blood.

Wikipedia: ⁷⁵ Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell dyscrasia in which plasma... more...

Sources

Related Diseases for Monoclonal Gammopathy of Uncertain Significance

Diseases related to Monoclonal Gammopathy of Uncertain Significance via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 522)

#	Related Disease	Score	Top Affiliating Genes
1	agammaglobulinemia	31.1	IL6 ICOSLG CD19
2	thrombocytopenia due to platelet alloimmunization	31.0	U2AF1 ICOSLG CD19
3	immunoglobulin light chain amyloidosis	31.0	SDC1 MYOM2 IGHV4-38-2 CD38 B2M
4	anemia, autoimmune hemolytic	31.0	IL6 IGHV4-38-2 ICOSLG CD38 CD19
5	lymphoma, mucosa-associated lymphoid type	30.9	SDC1 IGHV4-38-2 ICOSLG CD19 B2M
6	chronic inflammatory demyelinating polyradiculoneuropathy	30.8	MYOM2 MAG ICOSLG
7	splenic marginal zone lymphoma	30.8	U2AF1 IGHV4-38-2 CD19
8	hypersensitivity reaction type iv disease	30.7	IL6 ICOSLG CD19
9	demyelinating polyneuropathy	30.7	MYOM2 MAG IL6
10	common variable immunodeficiency	30.6	IL6 ICOSLG CD38 CD19
11	solitary osseous plasmacytoma	30.6	SDC1 NCAM1 MYOM2 IGHV4-38-2 CD38 B2M
12	bone disease	30.5	NSD2 IL6 ICOSLG FGFR3 B2M
13	skin disease	30.5	U2AF1 NCAM1 IL6 ICOSLG FGFR3 CD19
14	leukemia, chronic myeloid	30.5	U2AF1 MIR19A IL6 ICOSLG CD38 CD19
15	waldenstroem's macroglobulinemia	30.5	SDC1 MYOM2 MAG IGHV4-38-2 CD38 CD19
16	extramedullary plasmacytoma	30.5	SDC1 NCAM1 MYOM2 IGHV4-38-2 CD38 CD19
17	lymphoplasmacytic lymphoma	30.4	SDC1 MYOM2 MAG IGHV4-38-2 CD38 CD19
18	myeloma, multiple	30.4	U2AF1 SDC1 NSD2 NCAM1 MYOM2 MIR19A
19	heavy chain disease	30.4	MYOM2 IGHV4-38-2
20	myelodysplastic syndrome	30.3	U2AF1 NCAM1 IL6 ICOSLG CD38 CD19
21	mantle cell lymphoma	30.3	U2AF1 SDC1 IL6 IGHV4-38-2 ICOSLG CD38
22	connective tissue disease	30.3	U2AF1 MIR30D MIR19A IL6 ICOSLG FGFR3
23	plasmacytoma	30.3	NCAM1 IL6 CD38 B2M
24	peripheral nervous system disease	30.2	U2AF1 NCAM1 MYOM2 MAG IL6 ICOSLG
25	gamma heavy chain disease	30.1	SDC1 IGHV4-38-2 CD38 CD19
26	plasmablastic lymphoma	30.1	SLAMF7 SDC1 IGHV4-38-2 CD38
27	exanthem	30.1	IL6 ICOSLG CD19
28	diffuse large b-cell lymphoma	30.1	U2AF1 IGHV4-38-2 ICOSLG CD19
29	pancytopenia	30.0	U2AF1 NCAM1 IL6 CD19
30	marginal zone b-cell lymphoma	30.0	U2AF1 SDC1 IGHV4-38-2 ICOSLG CD38 CD19
31	leukemia, acute lymphoblastic	30.0	U2AF1 IGHV4-38-2 ICOSLG CD38 CD19
32	leukemia, acute myeloid	29.9	U2AF1 SDC1 NCAM1 MIR30D IL6 IGHV4-38-2
33	deficiency anemia	29.9	U2AF1 IL6 ICOSLG CD38 CD19 B2M
34	leukemia, chronic lymphocytic	29.8	U2AF1 SDC1 NCAM1 MIR30D MIR19A IL6
35	smoldering myeloma	29.7	TENT5C SLAMF7 SDC1 NSD2 NCAM1 MYOM2
36	severe combined immunodeficiency	29.6	IL6 ICOSLG CD38 CD19
37	lymphoma, non-hodgkin, familial	29.6	U2AF1 SDC1 NCAM1 IL6 IGHV4-38-2 ICOSLG
38	plasma cell neoplasm	29.5	U2AF1 SDC1 NCAM1 MYOM2 IL6 IGHV4-38-2
39	bone marrow cancer	29.5	U2AF1 SLAMF7 SDC1 NSD2 NCAM1 MYOM2
40	plasma cell leukemia	29.1	TENT5C SLAMF7 SDC1 NSD2 NCAM1 MYOM2
41	light chain deposition disease	11.7
42	macroglobulinemia, waldenstrom 1	11.1
43	thrombophilia due to thrombin defect	10.6
44	vasculitis	10.6
45	nephrotic syndrome	10.5
46	axonal neuropathy	10.5
47	body mass index quantitative trait locus 11	10.5
48	agammaglobulinemia, x-linked	10.5
49	chronic neutrophilic leukemia	10.5
50	myeloproliferative neoplasm	10.5

Graphical network of the top 20 diseases related to Monoclonal Gammopathy of Uncertain Significance:

Sources

Symptoms & Phenotypes for Monoclonal Gammopathy of Uncertain Significance

MGI Mouse Phenotypes related to Monoclonal Gammopathy of Uncertain Significance:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	immune system	MP:0005387	10	B2M CD19 CD38 DIS3 FGFR3 ICOSLG
2	hematopoietic system	MP:0005397	9.77	B2M CD19 CD38 DIS3 FGFR3 ICOSLG
3	integument	MP:0010771	9.28	B2M CD19 FGFR3 IL6 MAF MYOM2

Sources

Drugs & Therapeutics for Monoclonal Gammopathy of Uncertain Significance

Drugs for Monoclonal Gammopathy of Uncertain Significance (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Celecoxib

Approved, Investigational

Phase 2

169590-42-5

2662

Sodium fluoride

Approved

Phase 2

7681-49-4

Curcumin

Approved, Investigational

Phase 2

458-37-7, 84765-67-3

969516

Metformin

Approved

Phase 2

1115-70-4, 657-24-9

4091

Acetaminophen

Approved

Phase 2

103-90-2

1983

Acalabrutinib

Approved, Investigational

Phase 2

1420477-60-6

71226663 71226662

Daratumumab

Approved

Phase 2

945721-28-8

Lenalidomide

Approved

Phase 2

191732-72-6

216326

Cianidanol

Approved, Withdrawn

Phase 2

154-23-4

9064

Rituximab

Approved

Phase 2

174722-31-7

Piperine

Investigational

Phase 2

94-62-2

638024

Epigallocatechin gallate

Investigational

Phase 2

989-51-5

65064

Epigallocatechin

Experimental, Investigational

Phase 2

970-74-1

72277

Epicatechin

Investigational

Phase 2

490-46-0

58571364 72276

Vaccines

Phase 2

Cyclooxygenase Inhibitors

Phase 2

Cyclooxygenase 2 Inhibitors

Phase 2

Radiopharmaceuticals

Phase 2

Listerine

Phase 2

Fluorodeoxyglucose F18

Phase 2

Fluorides

Phase 2

Chelating Agents

Phase 2

Antibodies, Monoclonal

Phase 2

Analgesics

Phase 2

Anti-Inflammatory Agents, Non-Steroidal

Phase 2

Analgesics, Non-Narcotic

Phase 2

Anti-Inflammatory Agents

Phase 2

Cytochrome P-450 Enzyme Inhibitors

Phase 2

Histamine H1 Antagonists

Phase 2

Histamine Antagonists

Phase 2

Immunoglobulins

Phase 2

Antibodies

Phase 2

Omega 3 Fatty Acid

Phase 2

Angiogenesis Inhibitors

Phase 2

Immunologic Factors

Phase 2

Antirheumatic Agents

Phase 2

Neuroprotective Agents

Phase 2

Antioxidants

Phase 2

Tea

Phase 2

Protective Agents

Phase 2

Antineoplastic Agents, Immunological

Phase 2

Siltuximab

Approved, Investigational

Phase 1

541502-14-1

Rifaximin

Approved, Investigational

Phase 1

80621-81-4

46783403 6436173

Liver Extracts

Phase 1

Imatinib Mesylate

Phase 1

220127-57-1

Protein Kinase Inhibitors

Phase 1

Anti-Bacterial Agents

Phase 1

Anti-Infective Agents

Phase 1

Gastrointestinal Agents

Phase 1

Altretamine

Approved

Early Phase 1

645-05-6

2123

Interventional clinical trials:

(show top 50) (show all 59)

#	Name	Status	NCT ID	Phase	Drugs
1	Reduction of Antigen-Lipid-Driven Monoclonal Gammopathies by Targeting Epicardial Fat and Its Lipids Content With Liraglutide: A Glucagon Like Peptide-1 Receptor Analogue (GLP-1RA)	Withdrawn	NCT02920190	Phase 4	Liraglutide
2	Double-blind Randomized Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy	Completed	NCT00259974	Phase 3	Rituximab
3	Biologic and Clinical Role of COX-2 Inhibitor (Celecoxib)in the Management of MGUS and Smoldering Myeloma	Completed	NCT00099047	Phase 2	celecoxib;placebo
4	A Pilot Study of Novel Imaging Modalities in Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), and Multiple Myeloma (MM)	Completed	NCT01237054	Phase 2	18-NaF PET;18-FDG PET/CT
5	Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (SHIVERING 2)	Completed	NCT02566265	Phase 2
6	A Single Arm, Multicenter, Phase II, Open-Label Trial to Evaluate Efficacy of Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance	Recruiting	NCT04614558	Phase 2	Isatuximab
7	Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopathy of Unknown Significance (MGUS), Low-risk Smoldering Multiple Myeloma (SMM) or Early Stage Prostate Cancer: A Pilot Study	Recruiting	NCT04731844	Phase 2	Curcumin plus Piperine
8	A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma	Recruiting	NCT04850846	Phase 2	Metformin XR
9	Phase II Study on Acalabrutinib and Anti-CD20 Antibody in Patients With Anti-MAG Mediated Neuropathy	Recruiting	NCT05065554	Phase 2	Acalabrutinib;Rituximab
10	Randomized Double-Blind Phase 2 Trial of Ibrutinib Versus Standard Treatment for COVID-19 Illness Requiring Hospitalization With Safety Lead-In	Active, not recruiting	NCT04439006	Phase 2	Ibrutinib
11	A Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma	Active, not recruiting	NCT03236428	Phase 2	Daratumumab
12	Isatuximab in Type I Cryoglobulinemia: A Prospective Pilot Study	Not yet recruiting	NCT05114109	Phase 2	Isatuximab Injection
13	A Phase II Trial of Lenalidomide as a Treatment for Neuropathy Associated With Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)	Terminated	NCT00665652	Phase 2	Lenalidomide
14	The Clinical and Biologic Evaluation of Polyphenon E, an Extract of Green Tea Containing EGCG, in Plasma Cell Dyscrasias - Pilot Study	Terminated	NCT00942422	Phase 2
15	Inhibition of Nuclear Factor Kappa B for Prevention of Disease Progression in Indolent B Cell Malignancies	Terminated	NCT00899353	Phase 2
16	A Phase II Trial of Rituximab for Peripheral Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance (MGUS)	Terminated	NCT00588822	Phase 2
17	Novel Imaging Modalities to Characterize Angiogenesis in the Bone Marrow Microenvironment in Multiple Myeloma (MM) and Its Precursor Disease	Withdrawn	NCT01571726	Phase 2	Fluciclatide
18	A Phase I Pharmacokinetic Study of STI571 in Patients With Advanced Malignancies and Varying Levels of Liver Dysfunction	Completed	NCT00025415	Phase 1	imatinib mesylate
19	A Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) Effects on the QT Interval in Subjects With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma	Completed	NCT01219010	Phase 1
20	Pilot Study of Oral Rifaximin in Patients With Monoclonal Gammopathy	Recruiting	NCT03820817	Phase 1	Rifaximin
21	A Phase I Trial to Evaluate Safety and Immunogenicity of a Cytomegalovirus Peptide Vaccine Co-Injected With PF-03512676 Adjuvant in Recipients of Allogeneic Hematopoietic Stem Cell Transplant	Active, not recruiting	NCT01588015	Phase 1
22	Immunologic and Genetic Characteristics of Monoclonal Immunoglobulins in Patient With Tuberculosis	Unknown status	NCT00173264
23	Diagnosis of Monoclonal Gammopathy of Renal Significance in Patients With Paraproteinemias	Unknown status	NCT03629561
24	Understanding Monoclonal Gammopathy of Unknown Significance (MGUS): A Research Study to Investigate the Functional Consequences of Paraprotein Production in MGUS	Unknown status	NCT02933021
25	Frequency and Characteristics of Pruritus in Patients With Monoclonal Gammopathy	Completed	NCT03832140
26	A Diagnostic Screening Trial Seeking AL Amyloidosis Very Early	Completed	NCT02741999
27	Genomic and Psychosocial Effects of the Relaxation Response Resiliency Program (3RP) on Patients With MGUS and Smoldering Multiple Myeloma	Completed	NCT01955395
28	S0309, Myeloma Specimen Repository Protocol, Ancillary	Completed	NCT00919139
29	S0120, A Prospective Observational Biologic Study of Asymptomatic Patients With Monoclonal Gammopathy and Plasmaproliferative Disorders	Completed	NCT00900263
30	The Development and Pilot Testing of a New Magnetic Resonance (MR) Imaging Protocol to Quantify Both Myeloma Disease Burden and Associated Bone Loss	Completed	NCT03951220
31	Prognostic Study of Markers of Angiogenesis and Coagulability in Patients With Monoclonal Gammopathy	Completed	NCT01543100
32	A Prospective Study Of Circulating Multiple Myeloma Cells As A Biomarker Of Progression In Myeloma Precursor States (MGUS And SMM)	Completed	NCT01958528
33	Study of Biomarkers of Exposure and Effects in Agriculture	Completed	NCT01139476
34	Sleep Apnea in Patients With MGUS and MM	Recruiting	NCT04114084
35	Screening to Improve Survival in AL Amyloidosis	Recruiting	NCT04615572
36	Study of Precursor Hematological Malignancies to Assess the Relationship Between Molecular Events of Progression and Clinical Outcome	Recruiting	NCT02269592
37	Prospective Observational Study of Clinical and Genomic Predictors of Progression to Myeloma in Asymptomatic Monoclonal Gammopathies	Recruiting	NCT02726750
38	A Randomized Placebo Controlled Study of a Plant-Based Dietary Versus Supplement Versus Placebo Intervention in Patients With Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - The Nutrition Prevention (NUTRIVENTION3) Study	Recruiting	NCT05640843
39	Registry for Adults With Plasma Cell Disorders (PCD's)	Recruiting	NCT03717844
40	Prospective Observation of the Incidence and Natural History of Monoclonal Gammopathy in Patients Undergoing Weight Reduction Surgery	Recruiting	NCT03855878
41	Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Myeloma (SMM), and Multiple Myeloma Patient Experience With COVID-19 Survey	Recruiting	NCT04727294
42	A Prospective Cohort Study of Patients With Plasma Cell Disorders (PCDs) in PKUFH	Recruiting	NCT05283993
43	Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies	Recruiting	NCT05136807
44	A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients With Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering Multiple Myeloma (SMM) - The Nutrition Prevention (NUTRIVENTION) Study	Recruiting	NCT04920084
45	Monoclonal Gammopathies of Renal Significance: Clinical-histological Features of a Multicenter Case Series (MGRS Project)	Recruiting	NCT05119309
46	Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis	Recruiting	NCT01408225
47	Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions (TRANSFORMM)	Recruiting	NCT05361694
48	Characterising Risk and Biology Of Smouldering Myeloma for Early Detection Of Symptomatic Myeloma	Recruiting	NCT05047107
49	Dysregulation of Glutamine Metabolism in the Pathogenesis of Multiple Myeloma	Recruiting	NCT03119883
50	Spanish Registry of Patients With Diagnosis of IgM-MGUS, Asymptomatic & Symptomatic Waldenström Macroglobulinemia. Analysis of Clinical and Laboratory Features, Treatment and Outcomes.	Recruiting	NCT05093153

Search NIH Clinical Center for Monoclonal Gammopathy of Uncertain Significance

Sources

Genetic Tests for Monoclonal Gammopathy of Uncertain Significance

Sources

Anatomical Context for Monoclonal Gammopathy of Uncertain Significance

Organs/tissues related to Monoclonal Gammopathy of Uncertain Significance:

MalaCards : Bone Marrow, Bone, Liver, Prostate, Myeloid, T Cells, B Cells

Sources

Publications for Monoclonal Gammopathy of Uncertain Significance

Articles related to Monoclonal Gammopathy of Uncertain Significance:

(show top 50) (show all 2823)

#	Title	Authors	PMID	Year
1	Diagnosing Multiple Myeloma and Related Disorders. ⁶²	Moore AR	36270842	2023
2	CCL18 promotes migration and invasion of multiple myeloma cells and is associated with poor prognosis. ⁶²	Qiao B...Sun C	36455232	2022
3	Predictive Immune Markers for Disease Progression in Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance ⁶²	Isgor IS...Turkoz HK	35965418	2022
4	Successful use of lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal gammopathy. ⁶²	Green A...Yates SG	36194257	2022
5	SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance. ⁶²	Sgherza N...Musto P	36382051	2022
6	Prevalence of Monoclonal Gammopathy of Undetermined Significance in Black South African Men. ⁶²	Cicero KI...Neugut AI	36126958	2022
7	Identifying monoclonal gammopathy of undetermined significance from electronic health records. ⁶²	Tanenbaum HC...Chao CR	36464325	2022
8	Risk factors for severe infection and mortality in COVID-19 and monoclonal gammopathy of undetermined significance. ⁶²	Ho M...Kumar S	36096078	2022
9	Monoclonal gammopathy of undetermined significance (MGUS) characterized by refractory lower gastrointestinal postoperative bleeding with coagulopathy. ⁶²	Zhang S...Yang F	36457584	2022
10	Pathology of Initial Axon Segments in Chronic Inflammatory Demyelinating Polyradiculoneuropathy and Related Disorders. ⁶²	Dziadkowiak E...Koszewicz M	36362407	2022
11	MGUS and clonal hematopoiesis show unrelated clinical and biological trajectories in an older population cohort. ⁶²	Da Via MC...Bolli N	35390146	2022
12	Long term follow-up of complement parameters to improve the management of acquired angioedema due to C1-inhibitor deficiency. ⁶²	Polai Z...Farkas H	36387475	2022
13	Tubulointerstitial nephritis with IgA kappa-positive plasma cells in a patient with primary Sjögren's syndrome and monoclonal gammopathy. ⁶²	Sonomura K...Nakayama M	36367665	2022
14	Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia. ⁶²	Dogliotti I...Garcia-Sanz R	36435884	2022
15	Emergence of proteinase 3-antineutrophil cytoplasmic antibody-associated glomerulonephritis with mesangial immune deposition during the clinical course of IgG λ monoclonal gammopathy of uncertain significance. ⁶²	Ueno M...Fujigaki Y	35420387	2022
16	High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments. ⁶²	Fernandez N...Cho HJ	35945129	2022
17	Plasma cell neoplasms and related entities-evolution in diagnosis and classification. ⁶²	Fend F...Cook JR	36414803	2022
18	Cryoglobulinemic Vasculitis Associated with Monoclonal Gammopathy of Undetermined Significance Developed after Sustained Virologic Response of Hepatitis C: A Case Report. ⁶²	Ishitoku M...Hirata S	36384905	2022
19	Prospective Multireader Evaluation of Photon-counting CT for Multiple Myeloma Screening. ⁶²	Schwartz FR...McCrum E	36399038	2022
20	Acquired von Willebrand syndrome and lymphoid neoplasms: A review of malignancy management, and propositions of practical recommendations. ⁶²	Nicol C...Ianotto JC	36006003	2022
21	Co-occurrence of Three Systemic Diseases: ANCA-associated Vasculitis, Sjögren's syndrome and Sarcoidosis. ⁶²	Tsuji K...Wada J	36450474	2022
22	Cancer risk and gammopathies in 2123 adults with Gaucher disease type 1 in the International Gaucher Group Gaucher Registry. ⁶²	Rosenbloom BE...Mistry PK	36054609	2022
23	IgA vasculitis with underlying monoclonal IgA gammopathy: innovative therapeutic approach targeting plasma cells. A case series. ⁶²	Hankard A...MINHEMON, the SNMFI	35713822	2022
24	Coexistence of Post-essential Thrombocythemia Myelofibrosis With Monoclonal Gammopathy of Undetermined Significance: A Case Report. ⁶²	Allam SR...Khillan R	36348874	2022
25	The OTUD6B-LIN28B-MYC axis determines the proliferative state in multiple myeloma. ⁶²	Paulmann C...Bassermann F	36059274	2022
26	The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception. ⁶²	Dhodapkar MV	36194782	2022
27	An Analysis of M-protein in Plasma cell Dyscrasia Patients Identifies that IgG Lambda Subtype is More Commonly Associated with Normal Serum Free Light Chain (SFLC) Ratio. ⁶²	Singh MK...Nityanand S	36262785	2022
28	Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial. ⁶²	Bomback AS...Smith RJH	36217526	2022
29	Unraveling unique features of plasma cell clones in POEMS syndrome with single-cell analysis. ⁶²	Isshiki Y...Iwama A	36129760	2022
30	Anti-myelin-associated-glycoprotein neuropathy successfully treated with tirabrutinib. ⁶²	Yasuda H...Ando M	36247137	2022
31	Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia. ⁶²	Moreno DF...Fernandez de Larrea C	36210485	2022
32	Monoclonal Gammopathies in a Fracture Liaison Service. ⁶²	McCall B...Aaron RK	36173906	2022
33	Diagnostic relevance of 2-[18 F]-FDG PET/CT in patients recently diagnosed with monoclonal gammopathy of undetermined significance. ⁶²	Rudolphi-Solero T...Sanchez-Sanchez R	36222822	2022
34	Cardiovascular Associations With Monoclonal Gammopathy of Undetermined Significance: Real or Coincidental? ⁶²	Kapoor P...Rajkumar SV	36213348	2022
35	Concurrent Monoclonal Gammopathy of Undetermined Significance in a Patient With Maxillary Sinus Fungus Ball. ⁶²	Kim KS...Min HJ	36053198	2022
36	Prevalence of monoclonal gammopathy of undetermined significance in US black women. ⁶²	Bertrand KA...Kataria Y	35723873	2022
37	Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: Results of the iStopMM study. ⁶²	Long TE...Kristinsson SY	36100605	2022
38	Characterizing M-protein light chain glycosylation via mass spectrometry. ⁶²	Miller ID...Murray DL	36113628	2022
39	IgM monoclonal gammopathies of clinical significance: diagnosis and management. ⁶²	Khwaja J...Vos JM	35770530	2022
40	Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias. ⁶²	Rebmann Chigrinova E...Bacher U	36138464	2022
41	Steps towards a Multiple Myeloma Cure? ⁶²	Gozzetti A...Bocchia M	36143236	2022
42	Smoldering multiple myeloma current treatment algorithms. ⁶²	Rajkumar SV...Mateos MV	36064707	2022
43	Cardiovascular Morbidity in Monoclonal Gammopathy of Undetermined Significance: A Danish Nationwide Study. ⁶²	Schwartz B...Andersson C	36213365	2022
44	Revisiting the spectrum of IgM-related neuropathies in a large cohort of IgM monoclonal gammopathy. ⁶²	Bardel B...Plante-Bordeneuve V	35505107	2022
45	Agent Orange Exposure, Transformation From MGUS to Multiple Myeloma, and Outcomes in Veterans. ⁶²	Dodlapati J...Copeland LA	36426111	2022
46	Genome-wide profiling of 5-hydroxymethylcytosines in circulating cell-free DNA reveals population-specific pathways in the development of multiple myeloma. ⁶²	Chiu BC...Zhang W	35974364	2022
47	[Expression of miR-17-5p in the plasma of patients with multiple myeloma and its role in tumorigenesis and development]. ⁶²	Xiang P...Fang BJ	35970794	2022
48	A case of type I cryoglobulinaemia vasculitis associated with monoclonal gammopathy of undetermined significance exacerbated by a progression to multiple myeloma. ⁶²	Hng M...Chew TK	35482531	2022
49	Calorimetric Markers for Detection and Monitoring of Multiple Myeloma. ⁶²	Krumova S...Taneva SG	36010876	2022
50	Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study. ⁶²	Abella E...VAC-COV-GM-HMAR, KING Cohort Extension and [email protected] studies	35961779	2022

Sources

Genes for Monoclonal Gammopathy of Uncertain Significance

Genes related to Monoclonal Gammopathy of Uncertain Significance (0 elite genes):

(show all 39)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MYOM2	Myomesin 2	Protein Coding	8.73	DISEASES inferred ¹⁴
2	SDC1	Syndecan 1	Protein Coding	8.33	DISEASES inferred ¹⁴
3	ICOSLG	Inducible T Cell Costimulator Ligand	Protein Coding	8.25	DISEASES inferred ¹⁴ ¹⁴
4	MIR19A	MicroRNA 19a	RNA Gene	8.1	DISEASES inferred ¹⁴ ¹⁴
5	IGHV4-38-2	Immunoglobulin Heavy Variable 4-38-2	Protein Coding	7.81	DISEASES inferred ¹⁴
6	NSD2	Nuclear Receptor Binding SET Domain Protein 2	Protein Coding	7.63	DISEASES inferred ¹⁴
7	CD38	CD38 Molecule	Protein Coding	7.52	DISEASES inferred ¹⁴
8	B2M	Beta-2-Microglobulin	Protein Coding	7.32	DISEASES inferred ¹⁴
9	U2AF1	U2 Small Nuclear RNA Auxiliary Factor 1	Protein Coding	7.16	DISEASES inferred ¹⁴ ¹⁴
10	MAFB	MAF BZIP Transcription Factor B	Protein Coding	7.14	DISEASES inferred ¹⁴
11	TENT5C	Terminal Nucleotidyltransferase 5C	Protein Coding	7.13	DISEASES inferred ¹⁴
12	DIS3	DIS3 Homolog, Exosome Endoribonuclease And 3'-5' Exoribonuclease	Protein Coding	7.11	DISEASES inferred ¹⁴
13	MAG	Myelin Associated Glycoprotein	Protein Coding	7.04	DISEASES inferred ¹⁴
14	SLAMF7	SLAM Family Member 7	Protein Coding	7	DISEASES inferred ¹⁴
15	CD19	CD19 Molecule	Protein Coding	6.86	DISEASES inferred ¹⁴
16	MAF	MAF BZIP Transcription Factor	Protein Coding	6.81	DISEASES inferred ¹⁴
17	MIR30D	MicroRNA 30d	RNA Gene	6.79	DISEASES inferred ¹⁴ ¹⁴
18	NCAM1	Neural Cell Adhesion Molecule 1	Protein Coding	6.73	DISEASES inferred ¹⁴
19	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	6.73	DISEASES inferred ¹⁴
20	IL6	Interleukin 6	Protein Coding	6.59	DISEASES inferred ¹⁴
21	CFHR2	Complement Factor H Related 2	Protein Coding	6.59	DISEASES inferred ¹⁴ ¹⁴
22	CCND3	Cyclin D3	Protein Coding	6.58	DISEASES inferred ¹⁴
23	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	6.55	DISEASES inferred ¹⁴
24	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	6.52	DISEASES inferred ¹⁴ ¹⁴
25	CCND1	Cyclin D1	Protein Coding	6.48	DISEASES inferred ¹⁴
26	DKK1	Dickkopf WNT Signaling Pathway Inhibitor 1	Protein Coding	6.34	DISEASES inferred ¹⁴
27	TP53	Tumor Protein P53	Protein Coding	6.31	DISEASES inferred ¹⁴
28	MYD88	MYD88 Innate Immune Signal Transduction Adaptor	Protein Coding	6.27	DISEASES inferred ¹⁴
29	MIR126	MicroRNA 126	RNA Gene	6.27	DISEASES inferred ¹⁴ ¹⁴
30	IRF4	Interferon Regulatory Factor 4	Protein Coding	6.25	DISEASES inferred ¹⁴
31	CD27	CD27 Molecule	Protein Coding	6.2	DISEASES inferred ¹⁴
32	CKS1B	CDC28 Protein Kinase Regulatory Subunit 1B	Protein Coding	6.19	DISEASES inferred ¹⁴
33	PTPRC	Protein Tyrosine Phosphatase Receptor Type C	Protein Coding	6.17	DISEASES inferred ¹⁴
34	CD8A	CD8a Molecule	Protein Coding	6.16	DISEASES inferred ¹⁴
35	ALB	Albumin	Protein Coding	6.15	DISEASES inferred ¹⁴
36	TNFRSF17	TNF Receptor Superfamily Member 17	Protein Coding	6.14	DISEASES inferred ¹⁴
37	TNFSF13B	TNF Superfamily Member 13b	Protein Coding	6.14	DISEASES inferred ¹⁴
38	TNFSF11	TNF Superfamily Member 11	Protein Coding	6.13	DISEASES inferred ¹⁴
39	CRBN	Cereblon	Protein Coding	6.09	DISEASES inferred ¹⁴

Sources

Variations for Monoclonal Gammopathy of Uncertain Significance

Copy number variations for Monoclonal Gammopathy of Uncertain Significance from CNVD:

⁶

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	13350	1	1	125000000	Gain		Monoclonal gammopathy of undetermined significance
2	16482	1	125000000	249250621	Gain		Monoclonal gammopathy of undetermined significance
3	55476	11	53700000	135006516	Gain		Monoclonal gammopathy of undetermined significance
4	76533	13	32200000	40100000	Deletion	NBEA	Monoclonal gammopathy of undetermined significance
5	82835	14	17600000	107349540	Loss		Monoclonal gammopathy of undetermined significance
6	89754	15	19000000	102531392	Gain		Monoclonal gammopathy of undetermined significance
7	124088	19	1	26500000	Gain		Monoclonal gammopathy of undetermined significance
8	166137	3	1	91000000	Gain		Monoclonal gammopathy of undetermined significance
9	214491	6	61000000	171115067	Loss		Monoclonal gammopathy of undetermined significance
10	253951	9	49000000	141213431	Gain		Monoclonal gammopathy of undetermined significance

Sources

Expression for Monoclonal Gammopathy of Uncertain Significance

Search GEO for disease gene expression data for Monoclonal Gammopathy of Uncertain Significance.

Sources

Pathways for Monoclonal Gammopathy of Uncertain Significance

Pathways related to Monoclonal Gammopathy of Uncertain Significance according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	NF-kappaB Signaling ³	12.14	NCAM1 CD38 CD19 B2M
2	Mesenchymal Stem Cells and Lineage-specific Markers ⁶⁵	11.54	SDC1 NCAM1 IL6 CD19
3	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.33	NCAM1 IL6 CD38 CD19
4	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.11	SLAMF7 IL6 ICOSLG CD19
5	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.09	SDC1 NCAM1 IL6 CD38 CD19